JP4936626B2 - 癌およびその前段階に対する個体の免疫 - Google Patents

癌およびその前段階に対する個体の免疫 Download PDF

Info

Publication number
JP4936626B2
JP4936626B2 JP2001557585A JP2001557585A JP4936626B2 JP 4936626 B2 JP4936626 B2 JP 4936626B2 JP 2001557585 A JP2001557585 A JP 2001557585A JP 2001557585 A JP2001557585 A JP 2001557585A JP 4936626 B2 JP4936626 B2 JP 4936626B2
Authority
JP
Japan
Prior art keywords
cells
cancer
protein
pharmaceutical composition
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001557585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003522157A5 (enExample
JP2003522157A (ja
Inventor
クネーベル デーベリッツ，マグヌス フォン
リンネバッハー，ミヒァエル
ルディー，ヴォルフガング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2003522157A publication Critical patent/JP2003522157A/ja
Publication of JP2003522157A5 publication Critical patent/JP2003522157A5/ja
Application granted granted Critical
Publication of JP4936626B2 publication Critical patent/JP4936626B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2001557585A 2000-02-10 2001-02-07 癌およびその前段階に対する個体の免疫 Expired - Lifetime JP4936626B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10006033.1 2000-02-10
DE10006033A DE10006033B4 (de) 2000-02-10 2000-02-10 Immunisierung eines Individuums gegen Carcinome und ihre Vorstufen
PCT/DE2001/000470 WO2001058477A2 (de) 2000-02-10 2001-02-07 Immunisierung eines individuums gegen carcinome und ihre vorstufen

Publications (3)

Publication Number Publication Date
JP2003522157A JP2003522157A (ja) 2003-07-22
JP2003522157A5 JP2003522157A5 (enExample) 2008-03-27
JP4936626B2 true JP4936626B2 (ja) 2012-05-23

Family

ID=7630548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001557585A Expired - Lifetime JP4936626B2 (ja) 2000-02-10 2001-02-07 癌およびその前段階に対する個体の免疫

Country Status (9)

Country Link
US (3) US20030139334A1 (enExample)
EP (1) EP1253938B1 (enExample)
JP (1) JP4936626B2 (enExample)
AT (1) ATE360439T1 (enExample)
AU (1) AU2001239160A1 (enExample)
CA (1) CA2400007C (enExample)
DE (2) DE10006033B4 (enExample)
ES (1) ES2286108T3 (enExample)
WO (1) WO2001058477A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
RS50817B (sr) 2004-03-30 2010-08-31 Euro-Celtique S.A. Dozni oblik otporan na promene koji sadrži adsorbenti i sredstvo sa suprotnim dejstvom
US10279018B2 (en) * 2012-12-03 2019-05-07 Unity Biotechnology, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
CN103293308B (zh) * 2013-05-24 2014-11-26 尉军 一种检测肿瘤标志物p16抗原表位氨基酸序列及应用
CN111434674B (zh) * 2018-12-25 2024-02-09 上海细胞治疗集团有限公司 多肽组合物及其在癌症免疫治疗中的用途
CN111848732B (zh) * 2019-04-30 2024-03-12 上海细胞治疗集团有限公司 多肽组合物及疫苗

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045444A1 (en) * 1997-04-10 1998-10-15 The Regents Of The University Of California Vaccines with enhanced intracellular processing
WO1999002183A2 (en) * 1997-07-10 1999-01-21 Ctl Immunotherapies Corporation A method of inducing a ctl response
WO2000001845A2 (de) * 1998-07-01 2000-01-13 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Verfahren zur frühen diagnose von carcinomen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889169A (en) * 1991-05-16 1999-03-30 Cold Spring Harbor Laboratory Cell cycle regulatory protein p16 gene
AU7015396A (en) * 1995-09-07 1997-03-27 Health Research Incorporated Cyclin e variants and use thereof
US5723313A (en) * 1995-09-27 1998-03-03 St. Jude Children's Research Hospital ARF-p19, a novel regulator of the mammalian cell cycle
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
AU1099699A (en) * 1997-10-15 1999-05-03 President And Fellows Of Harvard College Cell regulatory genes, encoded products, and uses related thereto
US6066651A (en) 1997-10-29 2000-05-23 Ortho-Mcneil Pharmaceutical, Inc. Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders
CA2355901A1 (en) * 1998-12-17 2000-06-22 Cropdesign N.V. Plant cell cycle genes and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045444A1 (en) * 1997-04-10 1998-10-15 The Regents Of The University Of California Vaccines with enhanced intracellular processing
WO1999002183A2 (en) * 1997-07-10 1999-01-21 Ctl Immunotherapies Corporation A method of inducing a ctl response
WO2000001845A2 (de) * 1998-07-01 2000-01-13 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Verfahren zur frühen diagnose von carcinomen

Also Published As

Publication number Publication date
US20060210591A1 (en) 2006-09-21
CA2400007C (en) 2008-08-26
ATE360439T1 (de) 2007-05-15
DE50112401D1 (de) 2007-06-06
US8946171B2 (en) 2015-02-03
US7569538B2 (en) 2009-08-04
EP1253938A2 (de) 2002-11-06
WO2001058477A3 (de) 2002-04-11
CA2400007A1 (en) 2001-08-16
ES2286108T3 (es) 2007-12-01
DE10006033A1 (de) 2001-08-23
US20110064770A1 (en) 2011-03-17
DE10006033B4 (de) 2005-11-10
AU2001239160A1 (en) 2001-08-20
EP1253938B1 (de) 2007-04-25
US20030139334A1 (en) 2003-07-24
JP2003522157A (ja) 2003-07-22
WO2001058477A2 (de) 2001-08-16

Similar Documents

Publication Publication Date Title
RU2682726C9 (ru) Вакцинная композиция против злокачественной опухоли
ES2319286T3 (es) Epitopos inmunogenos de linfocitos t colaboradores de antigenos de tumor humanos y utilizacion de dichos epitopos en metodos inmunoterapeuticos.
US7148326B2 (en) Tumor antigen
KR101610353B1 (ko) Ｃｄｃａ１ 펩티드 및 이를 포함하는 약학적 조성물
ES2373055T3 (es) Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
US8946171B2 (en) Immunization of an individual against carcinomas and the preliminary stages thereof
JP2007516966A (ja) 合成ｈｌａ結合ペプチド類似体及びその使用方法
KR20170008873A (ko) B형 간염 바이러스 감염에 대한 치료 백신접종을 위한 합성 롱 펩티드(slp)
WO2014004385A2 (en) Anti-cancer vaccines
JP2001516226A (ja) 腫瘍関連性の抗原に対する免疫応答を誘導するための組成物および方法
JP5065273B2 (ja) Ｈｌａ−ａ２４分子結合性ｋｉｆ由来ペプチド
JP2005512517A (ja) 誘導性Ｈｓｐ７０由来のポリペプチドとこのポリペプチドを含有する医薬組成物
CA2600898C (en) Novel cancer antigen peptide and the use thereof
WO2001011044A1 (fr) Antigene de tumeur
JP2020125325A (ja) アスパラギン酸−β−ヒドロキシラーゼは腫瘍においてエピトープ特異的Ｔ細胞応答を誘導する
US20200024316A1 (en) Cacna1h-derived tumor antigen polypeptide and use thereof
RU2626542C2 (ru) ПЕПТИДЫ, ПОЛУЧЕННЫЕ ИЗ р16INK4a, ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВПЧ-АССОЦИИРОВАННЫХ ОПУХОЛЕЙ И ДРУГИХ ОПУХОЛЕЙ, ЭКСПРЕССИРУЮЩИХ р16INK4а
CN105330733A (zh) MHC II类分子提呈的存活蛋白（Survivin）的部分肽及其利用方法
JP2023525276A (ja) 延長された酸化還元酵素モチーフを有する免疫原性ペプチド
JP3876162B2 (ja) 肝細胞癌の治療のための方法及び組成物
JPWO2003037917A1 (ja) 腫瘍抗原
US20190224291A1 (en) Col14a1-derived tumor antigen polypeptide and use thereof
JP2014117194A (ja) ＨＰＶ関連腫瘍及び他のｐ１６ＩＮＫ４ａ発現腫瘍の予防法及び治療法のためのｐ１６ＩＮＫ４ａ由来ペプチド
JP2007520198A (ja) Ｍｍｐ−２タンパク質由来ペプチドおよび抗腫瘍免疫療法におけるその使用
JPWO2005075646A1 (ja) ストレス誘導抗アポトーシス分子（ｉｅｘ−１）由来ペプチド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110314

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110817

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110909

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111018

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120210

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120221

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150302

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4936626

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term